Management of NSAID-induced gastropathy: an economic decision analysis. (Q50627866)

16 March 2018

title

Management of NSAID-induced gastropathy: an economic decision analysis. (English)

1 reference

16 March 2018

1 reference

Goldstein JL

1

1 reference

16 March 2018

Larson LR

series ordinal

2

1 reference

16 March 2018

Yamashita BD

series ordinal

3

1 reference

16 March 2018

Boyd MS

series ordinal

4

1 reference

16 March 2018

publication date

1 November 1997

1 reference

16 March 2018

published in

Clinical Therapeutics

1 reference

16 March 2018

volume

19

1 reference

16 March 2018

issue

6

1 reference

16 March 2018

page(s)

1496-509; discussion 1424-5

1 reference

16 March 2018

Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986-1990

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Nonsteroidal anti-inflammatory drugs and the gut.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Natural history, symptomatology, and significance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Epidemiology and economics of NSAID-induced gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Gastrointestinal effects of NSAIDs. Difficulties in detection and management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980021-5

7 January 2021

10.1016/S0149-2918(97)80021-5

Identifiers

DOI

1 reference

16 March 2018

PubMed ID

9444455

1 reference

16 March 2018